• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Measles - Pipeline Review, H2 2012 Product Image

Measles - Pipeline Review, H2 2012

  • ID: 2233820
  • August 2012
  • 42 pages
  • Global Markets Direct

Measles – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Measles - Pipeline Review, H2 2012', provides an overview of the Measles therapeutic pipeline. This report provides information on the therapeutic development for Measles, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Measles. 'Measles - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Measles.
- A review of the Measles products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- READ MORE >

Note: Product cover images may vary from those shown

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Measles Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Measles 7
Measles Therapeutics under Development by Companies 9
Measles Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Discovery and Pre-Clinical Stage Products 13
Comparative Analysis 13
Measles Therapeutics – Products under Development by Companies 14
Measles Therapeutics – Products under Investigation by Universities/Institutes 15
Companies Involved in Measles Therapeutics Development 16
Sanofi-Aventis 16
GlaxoSmithKline plc 17
iBio, Inc. 18
Variation Biotechnologies, Inc. 19
Serum Institute of India Limited 20
Measles – Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Combination Products 22
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
Measles Vaccine - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Measles Vaccine - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Japanese Encephalitis Chimeric Virus Vaccine + MMR II Vaccine - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
GSK208136 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Adenovirus Vectored Vaccine - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Varilrix + Priorix-Tetra - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Thermostable IM Measles Vaccine - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Measles Therapeutics – Drug Profile Updates 36
Measles Therapeutics – Discontinued Products 37
Measles Therapeutics - Dormant Products 38
Measles – Product Development Milestones 39
Featured News & Press Releases 39
Mar 15, 2012: CHMP Adopts Positive Opinion Recommending Variation To Terms Of Marketing Authorization For Proquad 39
Sep 06, 2005: FDA Approves ProQuad, the First and Only Vaccine in the U.S. to Help Protect Children Against Measles, Mumps, Rubella and Chickenpox in One Shot. ProQuad Combines Two Well-Established Merck Vaccines, M-M-R II and VARIVAX. 39
Nov 04, 2004: Merck Files Biologics License Application for ProQuad With U.S. Food and Drug Administration. 40
May 13, 2004: ProQuad, Merck's Investigational Combination Vaccine, Resulted in Antibody Responses Similar to Those with M-M-R IIand Varivax in New Study. 40
Appendix 41
Methodology 41
Coverage 41
Secondary Research 41
Primary Research 41
Expert Panel Validation 41
Contact Us 42
Disclaimer 42

List of Tables
Number of Products Under Development for Measles, H2 2012 7
Products under Development for Measles – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 13
Products under Development by Companies, H2 2012 14
Products under Investigation by Universities/Institutes, H2 2012 15
Sanofi-Aventis, H2 2012 16
GlaxoSmithKline plc, H2 2012 17
iBio, Inc., H2 2012 18
Variation Biotechnologies, Inc., H2 2012 19
Serum Institute of India Limited, H2 2012 20
Assessment by Monotherapy Products, H2 2012 21
Assessment by Combination Products, H2 2012 22
Assessment by Stage and Route of Administration, H2 2012 24
Assessment by Stage and Molecule Type, H2 2012 26
Measles Therapeutics – Drug Profile Updates 36
Measles Therapeutics – Discontinued Products 37
Measles Therapeutics – Dormant Products 38

List of Figures
Number of Products under Development for Measles, H2 2012 7
Products under Development for Measles – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Discovery and Pre-Clinical Stage Products, H2 2012 13
Assessment by Monotherapy Products, H2 2012 21
Assessment by Combination Products, H2 2012 22
Assessment by Route of Administration, H2 2012 23
Assessment by Stage and Route of Administration, H2 2012 24
Assessment by Molecule Type, H2 2012 25
Assessment by Stage and Molecule Type, H2 2012 26

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos